Mehdi Hatami; Massoud Saidijam; Reza Yadegarzari; Shiva Borzuei; Alireza Soltanian; Marzieh Safi Arian; Mohammad Taghi Goodarzi

doi:10.4068/cmj.2016.52.3.201

Journal List > Chonnam Med J > v.52(3) > 1074968

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Hatami, Saidijam, Yadegarzari, Borzuei, Soltanian, Arian, and Goodarzi: Peroxisome Proliferator-Activated Receptor-γGene Expression and Its Association with Oxidative Stress in Patients with Metabolic Syndrome

Original Article

Chonnam Medical Journal 2016; 52(3): 201-206.

Published online: 23 September 2016

DOI: https://doi.org/10.4068/cmj.2016.52.3.201

Peroxisome Proliferator-Activated Receptor-γGene Expression and Its Association with Oxidative Stress in Patients with Metabolic Syndrome

Mehdi Hatami¹, Massoud Saidijam², Reza Yadegarzari², Shiva Borzuei³, Alireza Soltanian⁴, Marzieh Safi Arian¹, Mohammad Taghi Goodarzi²

¹Department of Clinical Biochemistry, Medical School, Hamadan University of Medical Sciences, Hamadan, Iran.

²Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.

³Department of Internal Medicine, Medical School, Hamadan University of Medical Sciences, Hamadan, Iran.

⁴Department of Biostatistics, Health School, Hamadan University of Medical Sciences, Hamadan, Iran.

Corresponding Author: Mohammad Taghi Goodarzi. Research Center for Molecular Medicine, Hamadan University of Medical Sciences, Shahid Fahmideh Blvd, Hamadan 65178, Iran. Tel: +988138380462, Fax: +988138380208, mt.goodarzi@umsha.ac.ir

Received 3 April 2016 Revised 2 May 2016 Accepted 10 May 2016

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Regulation of the peroxisome proliferator-activated receptor-γ (PPAR-γ) gene plays an important role in controlling the metabolism of lipids and inflammatory processes. Therefore, it can be associated with the pathogenesis of metabolic syndrome (MetS). The purpose of this study was to determine the expression of this gene in peripheral blood mononuclear cells (PBMC) in patients with metabolic syndrome. Using real-time polymerase chain reaction (PCR), mRNA expression of PPAR-γ was found in PBMC from 37 subjects with MetS and 30 healthy controls. Serum levels of glucose and lipid profiles were measured. The total antioxidant capacity (TAC) was measured using the ferric reducing ability of plasma (FRAP) test. Malondialdehyde (MDA) was determined using a fluorimetric method. Total oxidant status (TOS) in serum was assayed according to oxidation of ferric to ferrous in the presence of methyl orange. Super oxide dismutase (SOD) activity was measured using a Randox kit. Expression of PPAR-γ gene was significantly increased in patients with MetS compared to the control subjects (p=0.002). There was no difference in serum levels of TAC, MDA and SOD between the two study groups, but a significant difference was observed in the TOS (p=0.03). Serum levels of triglycerides and glucose were significantly higher in subjects with MetS. According to the results of our study, an increase in the expression of PPAR-γ in subjects with MetS indicated a possible role of PPAR-γ in the pathogenesis of this disease.

Keywords: Gene Expression, Metabolic Syndrome, Oxidative Stress, Peroxisome Proliferator-Activated Receptor γ

INTRODUCTION

Metabolic syndrome (MetS) is a cluster of various disorders which are characterized by the impairment of glucose tolerance or hyperglycemia, abdominal obesity, high blood pressure and dyslipidemia.1 Obesity and MetS are related to an increased risk of cardiovascular disease, type 2 diabetes mellitus, hypertension, hyperlipidemia, mortality and morbidity in certain cancers.2

These conditions are characterized by an altered oxidative/antioxidant status and by subclinical inflammation; both are responsible for the development of atherosclerosis. Recently there has been a focused interest on the role of oxidative stress in the commencement of the MetS and insulin resistance,3 4 5 Increase in the synthesis of reactive oxygen species (ROS) and/or failure of the defenses against the ROS cause MetS which lead to an increase in oxidative stress.6 Under normal physiological conditions, different antioxidant systems can eliminate or inactivate ROS and free radicals. Superoxide dismutase (SOD) enzymatically converts superoxide anions (O₂⁻) to hydrogen peroxide and subsequently hydrogen peroxide is disposed by the enzyme glutathione peroxidase (GSH-Px).6 7 On the other hand, catalase, a peroxisomes exclusive enzyme, detoxifies hydrogen peroxide. Furthermore, there are various molecules which eliminate or inactivate ROS-producing free radicals; endogenous molecules like uric acid and albumin and exogenous antioxidants derived from diet like ascorbic acid and vitamin E.7 The sum of endogenous and food-derived antioxidants represents the total antioxidant capacity (TAC) of the extracellular fluids.

The members of the superfamily of nuclear hormone receptors, peroxisome proliferator-activated receptors (PPARs), are ligand-dependent transcription factors which are predominantly expressed in adipose tissue and are known to be involved in differentiation of adipocyte and as the regulator of adipogenesis.8 9 Lower levels of PPAR-γ are expressed in other tissues such asskeletal muscle and liver tissues, which are the major target tissues for insulin.10 The expression of PPAR-γ has been shown in human peripheral blood mononuclear cells (PBMC), such as macrophages and monocytes,11 12 where it plays an important role in the regulation of the inflammatory processes like down regulation of proinflammatory mediators in macrophages.13 14

The anti-inflammatory effect of PPAR-γ is shown through its inhibitory effect on the production of inflammatory cytokines, such as tumor necrosis factor-α in the monocytes and nuclear factor kappa B (NF-kB) as well.14 15 A hypermetabolic state is associated with alterations in oxidative metabolism, increased production of free radicals and oxidative stress, and finally the acute phase response (APR).16 In adipose tissue, recently the APR has been shown to down-regulate PPAR-γ, which can be expected because PPAR-γ is generally anti-inflammatory and improves insulin sensitivity.17 18

Since PPAR-γ shows a role in inflammatory processes, it can be associated with the pathogenesis of MetS. The purpose of this study was to determine the expression of PPAR-γ gene in PBMC in patients with metabolic syndrome compared with the healthy control group. Determination of a possible correlation between the expression of the PPAR-γ gene and the anti-oxidant parameters in both normal and MetS groups was another aim in this study.

MATERIALS AND METHODS

1. Patients

Thirty healthy subjects who did not meet the criteria for metabolic syndrome and 37 patients with metabolic syndrome participated in this study. MetS was diagnosed when the candidates had at least three positive criteria out of the following: 1. Systolic blood pressure (SBP) ≥130 mmHg and diastolic blood pressure (DBP) ≥85 mmHg, 2. Fasting blood sugar (FBS) ≥6.05 mmoL/L or 100 mg/dL, 3. Waist circumference ≥90 cm in women, 4. High-density lipoprotein cholesterol (HDL-C) ≤50 mg/dL in women, 5. Triglycerides (TG) ≥ 150 mg/dL. Diabetic patients and subjects having blood hypertension, liver, kidney or thyroid disease were excluded from the study. Subjects who were on antihyper-lipidemic medications as well as pregnant women were also excluded. Overnight fasting blood samples of all the participants were taken and collected in three tubes for serum, plasma, using ethylenediamine tetra-acetic acid (EDTA), and PBMC preparation. Plasma and serum were separated by centrifugation (1,000 g, 5 min). Height, weight, waist circumference, systolic and diastolic blood pressures were also measured in all participants. The body mass index was calculated as well. The protocol of the study was approved by the Ethics Committee of Hamadan University of Medical Sciences, Hamadan, Iran, in accordance with the Helsinki Declaration. Written informed consent was acquired from all participants.

2. Measurement of biochemical factors

Serum samples were used to assess fasting blood glucose, total cholesterol, TG, high density lipoprotein cholesterol (HDL-C), and low density lipoprotein cholesterol (LDL-C) levels. Enzymatic calorimetric kits were used to measure serum levels of total cholesterol; triglyceride and blood glucose (ParsAzmun, Iran). The homogeneous enzymatic calorimetric test was used to measure the serum levels of LDL-C and HDL-C.

3. Isolation of peripheral blood mononuclear cell (PBMC), RNA extraction and c-DNA synthesis

The PBMCs were isolated from anticoagulant-treated blood samples using the Ficoll standard density gradient centrifugation (1,000 g; 5 min).12 Total RNA from PBMC samples was extracted using the column separation method. The isolated RNA was treated with DNase I (Fermentas Inc., Vilnius, Lithuania) to remove any possible DNA contamination; it was quantified at 260 nm using a nanodrop spectrophotometer (Eppendorf, Hamburg, Germany). The integrity of the RNA was verified by examining a optical density absorption ratio OD_{260 nm}/OD_{280 nm} that was between 1.8 and 2.0. The c-DNA was obtained from 1 µg of total sample of RNA.18 The obtained c-DNA was used as a template for real-time quantitative PCR.

4. Real-time quantitative PCR analysis

A quantitative, real-time PCR using a qPCR™ Green Master Kit for SYBR Green IW (Jena Biosciense, Gmbh, Germany) was developed for detecting relative mRNA levels of PPAR-γ in PBMCs, in real-time PCR detection system (Bio-Rad Laboratories, USA). Relative expression levels of PPAR-γ transcription were normalized to RNA loading for each sample using 18srRNA. Specific primers for all genes were designed using AlleleID7.6 software (version 7.6).

Sequences of sense and antisense primers for the PPAR-γ and reference gene (18s rRNA) are shown in Table 1.

The PCR reactions were performed on a final volume of 20 µL containing 1 µL cDNA, 7 µL deionized water, sense and antisense primers (1 µL of each) and 10 µL SYBR Green IW. The reactions were performed (in triplicate) with the following settings: 10 minutes of pre-incubation at 95℃ followed by 40 cycles for 30 seconds at 95℃ and 30 seconds at 72℃. A reaction without c-DNA was performed in parallel as a negative control.

Using the standard curve, a relative number of copies was obtained and normalized to values which were obtained for the reference control gene 18srRNA.19 To show the relative expression of PPAR-γ, fold change of expression was then calculated using the 2^−ΔΔct formula.20

5. Antioxidant analysis

The serum concentration of malondialdehyde (MDA) was analyzed by the thiobarbituric acid method.21 The TAC was determined by the ferric reducing/antioxidant power assay and detected at 520 nm using a spectrophotometer, as described by Benzie and Strain.22 Activity of SOD was assayed by the xanthine oxidase method using Randox kit (Randox Labs, Crumlin, UK),23 which monitors the degree of inhibition of nitrobluetetrazolium reduction through O₂⁻-generated by xanthine and xanthine oxidase. The absorbance was read at 550 nm using a spectrophotometer. The total oxidant status (TOS) was assessed using a new colorimetric assay method developed by Erel.24

6. Statistical analyses

Data analysis was carried out using the SPSS 18.0 software package (SPSS Inc., Chicago, IL, USA). Independent-samplest-test was used to measure the differences in studied parameters between two groups. All experimental data was presented as the mean±standard deviation (SD). The Spearman correlation coefficient was calculated to estimate the correlations between variables. Values were considered to be statistically significant when the p<0.05.

RESULTS

Comparisons of the baseline SBP and DBP, waist circumference, body mass index (BMI), and biochemical parameters between the studied groups are presented in Table 2. There were significant differences in the values for weight (p=0.001), body mass index (BMI) (p=0.001), waist circumstance (p=0.001) and SBP (p=0.002) between the two study groups despite no significant difference in DBP. Comparing biochemical parameters showed higher levels of fasting blood sugar (FBS) (p=0.001) and TG (p=0.029) in the subjects with MetS. There was no significant difference in total cholesterol (tChol), HDL-C and LDL-C between the study groups.

While none of the subjects in the control group had the criteria of MetS, some components of MetS were observed in some cases; waist circumference, HDL-C, TG and FBS in 17%, 13%, 10%, and 10% of controls subjects respectively.

The levels of the various oxidative stress factors are shown in Table 3. No significant differences in the levels of TAC, MDA and SOD were found between the two groups. The only parameter which had a significantly higher level in MetS group was TOS (p=0.03). Fig. 1 illustrates Δct of the PPAR-γ gene which is significantly lower in patients group compared to the healthy control group (p=0.002), which indicates a higher expression in MetS subjects. To further analyze the relative gene expression of PPAR-γ, the fold change of this gene in MetS group was calculated using the 2^−ΔΔCt formula. The obtained results showed a 9.5-fold higher expression of the PPAR-γ gene in the MetS group. The correlation of PPAR-γ gene expression with components of MetS was also determined. PPAR-γ gene expression in the MetS group showed a negative correlation with HDL-C (r=−0.35, p=0.03) and a positive correlation with TG (r=0.42, p=0.026). No statistically significant correlation was observed between PPAR-γ gene expression and the other components of MetS in both groups. Furthermore, there was no correlation between expression of the PPAR-γgene and the anti-oxidant parameters in both normal and MetS groups.

DISCUSSION

In this study we evaluated the expression of the PPAR-γ gene in MetS subjects. We also examined any association between MetS, serum lipid variation, and oxidative state. MetS is a multi-factorial disorder and its causes have not been precisely determined. The higher expression of PPAR-γ was observed in MetS subjects compared to healthy control group. The PPAR-γ is a ligand-activated transcription factor belonging to the nuclear receptor superfamily which plays a critical role in the metabolism of lipids and glucose.9 It enhances macrophage lipid uptake as well as lipid export.13 It has been shown that PPAR-γ can be expressed in both adipocyte and human PBMCs and the higher expression of this gene was seen after consumption of a high-fat meal in healthy individuals.8 Anti-inflammatory properties of PPAR-γ have been extensively reviewed in other studies.25 26 In obesity, production of inflammatory cytokines TNFα, IL-1β and IL-6 result in a wide range of metabolic changes. It has been shown that TNFα and IL-1 directly decrease the levels of PPAR-γ.18

We found higher levels of PPAR-γ expression in the PBMCs of patients with MetS, which was associated with a significant higher plasma level of TG. Garcia-Fuentes et al. studied PPAR-γ expression in PBMCs in morbidly obese persons.27 They found that the reduction in the expression of PPAR-γ is correlated with the increase in free fatty acids.27

The alteration in oxidative metabolism is accompanied by an increase in the production of free radicals and oxidative stress parameters that may induce a hypermetabolic state and APR.28 29 There is evidence that PPAR-γ ligands can increase the expression and activity of Cu/Zn SOD and decrease the expression of the NADPH oxidase subunit in vascular-endothelial cells, in vitro.30 The relation between this gene and antioxidant parameters was examined in our study. No correlation was observed between the levels of PPAR-γ and antioxidant parameters. These results did not support our hypothesis that PPAR-γ affects these parameters. Higher expression of the PPAR-γ gene, which was observed in the MetS group in this study, was similar to the findings in the study by Macias-Gonzalez et al.31 In their study, PPAR-γ expression was higher in patients compared to healthy subjects. However, down-regulation of PPAR-γ was observed in MetS patients after a fat overload compared with baseline level. In contrast, healthy subjects experienced an increase in the expression levels of PPAR-γ after fat overload.31 Decreased inexpression of PPAR-γ gene can explain the base concept of "saturation", derived from a limitation in the expandability of fat and peripheral lipid metabolism, in pathophysiological situations.32 This saturation in lipid balance can lead to lipotoxicity which ends in saturation of the antioxidant machinery and could finally affect the regulation of PPAR-γ expression.31

Interestingly, Garcia-Fuentes et al. showed that in a group of morbidly obese persons, plasma SOD activity and mRNA expression of PPAR-γ were decreased after taking a high-fat meal.27 Also they indicated that PPAR-γ expression after the high-fat meal was correlated with the plasma SOD activity.27

It can be hypothesized that the activation of PPAR-γ in our study might favor adipocyte differentiation, resulting in a decrease in the inflammatory status of adipose tissue during obesity. Diet induced obesity is associated with increased inflammatory gene expression in adipose tissue via adipocyte hypertrophy and macrophage infiltration. It has been shown that PPAR-γ is able to reverse macrophage infiltration, and subsequently reduces the expression of inflammatory genes.33 Moreover, it can be suggested that reactivating PPAR-γ could be a response in order to restore the metabolic balance in MetS.

In our study, the increase in antioxidant parameters showed no significant changes; however, the TOS was significantly higher which could indicate the increase in lipotoxicity.

We did not observe a significant association between expression of the PPAR-γ gene and the oxidative stress status in MetS patients; however, it could be due to the limited number of subjects in this study.

The scientists believe that the contributed mechanisms to the pathogenesis of MetS are still in need of intense investigation.34 There is an alteration in expression of some genes in MetS that can lead to obesity, diabetes mellitus, and hypertension. Recently we have shown that ABCG1 gene expression, one of the ABC transmembrane transporters, significantly decreases in MetS.35 Down-regulation of ABCG1 can affect cholesterol efflux and predispose patients to atherosclerosis.

Also there are some changes in the expression of some cytokines' genes in MetS. An increase in the expression of the leptin receptor gene and a decrease in the expression of IL-10 and IL-8 have been reported in MetS.36 37 On the other hand, no significant changes has been observed in the expression of IL-7.37 It is believed that MetS is caused by the chronic activation of the innate immune system, which can contribute to the some components of MetS.28 Changes in the above mentioned cytokines, leptin receptors and PPAR-γ may play a role in this condition. PPAR-γ plays an important role in metabolic balance.

An increase in expression of the PPAR-γ gene in subjects with MetS in our results indicates a possible role in the pathogenesis of this disease. This up-regulation of the PPAR-γgene can be a physiologic response to increased resistance to oxidative stress.

Figures and Tables

FIG. 1

PPARγ mRNA expression level (ΔCt) in peripheral blood mononuclear cells of metabolic syndrome subjects compared with normal control group. The results are given as mean±standard deviation. ^*p=0.002. PPAR: peroxisome proliferator-activated receptor, MetS: metabolic syndrome.

TABLE 1

Primers used in amplification of PPAR-γ and 18s rRNA genes

F: forward primer, R: reverse primer, Tm: melting temperature, GC%: percentage of guanosine and cytosine nucleotides.

TABLE 2

Anthropometric and biochemical parameters in metabolic syndrome patients and healthy control subjects

Data are Mean±SD. MetS: metabolic syndrome, BMI: body mass index, FBS: fasting blood sugar, tChol: total cholesterol, TG: triglycerides, HDL-c: high density lipoprotein cholesterol, LDL-c: low density lipoprotein cholesterol.

TABLE 3

Different parameters of oxidative stress in metabolic syndrome patients and controls

Data are expressed as Mean±SD. MetS: Metabolic syndrome, TAC: total antioxidant capacity, TOS: total oxidant status, SOD: superoxide dismutase activity, MDA: malondialdehyde.

ACKNOWLEDGEMENTS

This work was supported by a grant from the Hamadan University of Medical Science. This article is extracted from M. Hatami MSc thesis.

Notes

^{CONFLICT OF INTEREST STATEMENT} None declared.

References

1. Weiss R, Bremer AA, Lustig RH. What is metabolic syndrome, and why are children getting it? Ann N Y Acad Sci. 2013; 1281:123–140.

2. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009; 120:1640–1645.

3. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest. 2004; 114:1752–1761.

4. Lirussi F, Azzalini L, Orando S, Orlando R, Angelico F. Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev. 2007; (1):CD004996.

5. Fujita K, Nishizawa H, Funahashi T, Shimomura I, Shimabukuro M. Systemic oxidative stress is associated with visceral fat accumulation and the metabolic syndrome. Circ J. 2006; 70:1437–1442.

6. Victor VM, Rocha M, Herance R, Hernandez-Mijares A. Oxidative stress and mitochondrial dysfunction in type 2 diabetes. Curr Pharm Des. 2011; 17:3947–3958.

7. Del Ben M, Angelico F, Cangemi R, Loffredo L, Carnevale R, Augelletti T, et al. Moderate weight loss decreases oxidative stress and increases antioxidant status in patients with metabolic syndrome. ISRN Obes. 2012; 2012:960427.

8. Dong C, Zhou H, Shen C, Yu LG, Ding Y, Zhang YH, et al. Role of peroxisome proliferator-activated receptors gene polymorphisms in type 2 diabetes and metabolic syndrome. World J Diabetes. 2015; 6:654–661.

9. Grygiel-Górniak B. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications--a review. Nutr J. 2014; 13:17.

10. Seok H, Cha BS. Refocusing peroxisome proliferator activated receptor-α: a new insight for therapeutic roles in diabetes. Diabetes Metab J. 2013; 37:326–332.

11. Setoguchi K, Misaki Y, Terauchi Y, Yamauchi T, Kawahata K, Kadowaki T, et al. Peroxisome proliferator-activated receptor-gamma haploinsufficiency enhances B cell proliferative responses and exacerbates experimentally induced arthritis. J Clin Invest. 2001; 108:1667–1675.

12. Klotz L, Schmidt M, Giese T, Sastre M, Knolle P, Klockgether T, et al. Proinflammatory stimulation and pioglitazone treatment regulate peroxisome proliferator-activated receptor gamma levels in peripheral blood mononuclear cells from healthy controls and multiple sclerosis patients. J Immunol. 2005; 175:4948–4955.

13. Stienstra R, Duval C, Müller M, Kersten S. PPARs, Obesity, and Inflammation. PPAR Res. 2007; 2007:95974.

14. Narala VR, Subramani PA, Narasimha VR, Shaik FB, Panati K. The role of nitrated fatty acids and peroxisome proliferator-activated receptor gamma in modulating inflammation. Int Immunopharmacol. 2014; 23:283–287.

15. Sharma AM, Staels B. Review: peroxisome proliferator-activated receptor gamma and adipose tissue--understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab. 2007; 92:386–395.

16. Hopps E, Noto D, Caimi G, Averna MR. A novel component of the metabolic syndrome: the oxidative stress. Nutr Metab Cardiovasc Dis. 2010; 20:72–77.

17. Lu B, Moser AH, Shigenaga JK, Feingold KR, Grunfeld C. Type II nuclear hormone receptors, coactivator, and target gene repression in adipose tissue in the acute-phase response. J Lipid Res. 2006; 47:2179–2190.

18. Kim MS, Sweeney TR, Shigenaga JK, Chui LG, Moser A, Grunfeld C, et al. Tumor necrosis factor and interleukin 1 decrease RXRalpha, PPARalpha, PPARgamma, LXRalpha, and the coactivators SRC-1, PGC-1alpha, and PGC-1beta in liver cells. Metabolism. 2007; 56:267–279.

19. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001; 29:e45.

20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001; 25:402–408.

21. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979; 95:351–358.

22. Benzie IF, Strain JJ. Ferric reducing/antioxidant power assay: direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic acid concentration. Methods Enzymol. 1999; 299:15–27.

23. Winterbourn CC, Hawkins RE, Brian M, Carrell RW. The estimation of red cell superoxide dismutase activity. J Lab Clin Med. 1975; 85:337–341.

24. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005; 38:1103–1111.

25. Szanto A, Nagy L. The many faces of PPARgamma: anti-inflammatory by any means? Immunobiology. 2008; 213:789–803.

26. Zingarelli B, Cook JA. Peroxisome proliferator-activated receptor-gamma is a new therapeutic target in sepsis and inflammation. Shock. 2005; 23:393–399.

27. Garcia-Fuentes E, Murri M, Garrido-Sanchez L, Garcia-Serrano S, García-Almeida JM, Moreno-Santos I, et al. PPARgamma expression after a high-fat meal is associated with plasma superoxide dismutase activity in morbidly obese persons. Obesity (Silver Spring). 2010; 18:952–958.

28. Nunn AV, Bell J, Barter P. The integration of lipid-sensing and anti-inflammatory effects: how the PPARs play a role in metabolic balance. Nucl Recept. 2007; 5:1.

29. Leclercq IA, Da Silva Morais A, Schroyen B, Van Hul N, Geerts A. Insulin resistance in hepatocytes and sinusoidal liver cells: mechanisms and consequences. J Hepatol. 2007; 47:142–156.

30. Hwang J, Kleinhenz DJ, Lassègue B, Griendling KK, Dikalov S, Hart CM. Peroxisome proliferator-activated receptor-gamma ligands regulate endothelial membrane superoxide production. Am J Physiol Cell Physiol. 2005; 288:C899–C905.

31. Macias-Gonzalez M, Cardona F, Queipo-Ortuño M, Bernal R, Martin M, Tinahones FJ. PPARgamma mRNA expression is reduced in peripheral blood mononuclear cells after fat overload in patients with metabolic syndrome. J Nutr. 2008; 138:903–907.

32. Medina-Gomez G, Gray SL, Yetukuri L, Shimomura K, Virtue S, Campbell M, et al. PPAR gamma 2 prevents lipotoxicity by controlling adipose tissue expandability and peripheral lipid metabolism. PLoS Genet. 2007; 3:e64.

33. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest. 2003; 112:1821–1830.

34. Kassi E, Pervanidou P, Kaltsas G, Chrousos G. Metabolic syndrome: definitions and controversies. BMC Med. 2011; 9:48.

35. Tavoosi Z, Moradi-Sardareh H, Saidijam M, Yadegarazari R, Borzuei S, Soltanian A, et al. Cholesterol Transporters ABCA1 and ABCG1 Gene Expression in Peripheral Blood Mononuclear Cells in Patients with Metabolic Syndrome. Cholesterol. 2015; 2015:682904.

36. Tootoonchi AS, Goodarzi MT, Hassanzadeh T, BorzueiSh , Yadegarazari R, Shabab N, et al. The expression of interleukins 10 and leptin receptor in peripheral mononuclear cells from patients with metabolic syndrome. J Basic Appl Sci Res. 2012; 2:10055–10062.

37. Saidijam M, Tootoonchi AS, Goodarzi MT, Hassanzadeh T, Borzuei SH, Yadegarazari R, et al. Expression of interleukins 7 & 8 in peripheral blood mononuclear cells from patients with metabolic syndrome: a preliminary study. Indian J Med Res. 2014; 140:238–243.